Vyloy 300 MG Injection
- RxCUI
- 2710432
- RxNorm name
- Vyloy 300 MG Injection
- Display name
- Vyloy 300 MG Injection
- Full name
- Vyloy 300 MG Injection
- Term type
- SY
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:25
Purple Book Biologic Products#
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 761365 | Vyloy | zolbetuximab-clzb | 351(a) | Rx | 2026-06-01 |
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| VYLOY | ZOLBETUXIMAB | Astellas Pharma US, Inc. | e7695a21-abb6-47ac-93f8-0ece5a9c4409 | 2025-06-12 | Warnings, Adverse reactions | 2710432 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm string | TTY | SPL version | Label | Effective |
|---|---|---|---|---|---|
| e7695a21-abb6-47ac-93f8-0ece5a9c4409 | Vyloy 300 MG Injection | SY | 4 | These highlights do not include all the information needed to use VYLOY safely and effectively. See full prescribing information for VYLOY. VYLOY ® (zolbetuximab-clzb) for injection, for intravenous use Initial U.S. Approval: 2024 | 20250612 |
| e7695a21-abb6-47ac-93f8-0ece5a9c4409 | zolbetuximab-clzb 300 MG Injection [Vyloy] | SBD | 4 | These highlights do not include all the information needed to use VYLOY safely and effectively. See full prescribing information for VYLOY. VYLOY ® (zolbetuximab-clzb) for injection, for intravenous use Initial U.S. Approval: 2024 | 20250612 |
| e7695a21-abb6-47ac-93f8-0ece5a9c4409 | VYLOY 300 MG Injection | PSN | 4 | These highlights do not include all the information needed to use VYLOY safely and effectively. See full prescribing information for VYLOY. VYLOY ® (zolbetuximab-clzb) for injection, for intravenous use Initial U.S. Approval: 2024 | 20250612 |